New York – September 17, 2015 – The largest bioprocessing event in the country, the 12th Annual BioProcess International (BPI) Conference & Exposition, will feature five keynote speakers addressing attendees on Tuesday, October 27 and Wednesday, October 28, in Boston. Hosted by IBC Life Sciences USA, an Informa company, the keynotes are part of the show’s conference and exposition to introduce new ideas, demystify technologies, and foster partnerships so that attendees can accelerate drug candidates closer to approval.
The distinguished speakers hail from some of the most highly-recognized companies and research institutions, both at home and abroad. Speaking to approximately 1,600 bioprocessing professionals from large, mid-size, and emerging biotech companies as well as big pharma, these industry leaders will deliver visionary insights regarding new strategies that propel life-saving drugs to market more quickly and efficiently, while maintaining the utmost in quality and safety standards. Three keynotes will be presenting on October 27, the first day of the exposition.
David J. Pollard, Ph.D., Executive Director, BioProcess Development, Merck & Co. Inc. –
Innovating mAb Production to Support the Immunotherapy Revolution
Dr. Pollard will discuss a new paradigm in cancer therapy emerging due to the recent success of the antibody-mediated, immune tumor-killing response for melanoma. Evaluations have expanded to include a range of tumor types, and new alternatives and combinations are aimed at improving patient non-responsiveness to PD-1. Dr. Pollard will examine the benefits and challenges inherent in new technology solutions implemented to speed process development and shorten the critical time to first-in-human clinical studies.
Spencer Fisk, Global Head, Biologics Process R&D, Novartis Pharma AG, Switzerland –
Innovative Process Development Strategies to Drive the Rapid Clinical Introduction of Emerging Biologics
The seamless integration from the research bench to the clinic required to move a large portfolio consisting of a broad spectrum of biological molecule-modalities will be explained by Dr. Fisk. He will speak about the deep alignment and partnership between the research and the process/analytics functions that allow for rapid and systematic product candidate screening. The combination of state-of-the-art cell lines with a regimented application of robust high-throughput process and analytical development packages that enable the possibility of reaching the first patient in record time using minimal resources will also be presented.
Michael Anthony (Tony) Moody, M.D., Chief Medical Officer, Associate Professor of Pediatrics, Duke Human Vaccine Institute (DHVI) –
Novel Approach to Developing and Producing Human Experimental Vaccines for HIV
Dr. Moody has devoted much of his research to understanding the B cell responses during the earliest stages of HIV infection. In this keynote, he will discuss new developments stemming from the Laboratory of B cell Immunotechnology at DHVI. The lab is one of several working on the Antibodyome project, which seeks to understand the repertoire of antibodies produced in response to vaccination and infection. The lab also continues to work on the development of new flow cytometric panels and reagents that can enhance the detection of B cell responses during the acute/early HIV infection.
The topics discussed in the keynotes complement the six conference tracks at BPI 2015. Attendees have access to all tracks and are encouraged to create personalized pathways and cross-fertilize ideas with attendees from different disciplines. They can choose from Analytical, Formulation, & Quality; Cell Culture & Upstream Processing; Drug Product Manufacturing & Fill-Finish Processing; Early Stage Biologics & Companies; Manufacturing Strategy; and Recovery & Purification.
To access exclusive podcast interviews with BPI speakers, visit www.bioprocessintl.com/bpi-2015-podcasts.
About BPI Conference & Exposition
BPI, an IBC USA conference and exposition, is the largest bioprocessing event that brings attendees new ideas, helps advance and explain technologies, and fosters partnerships in highly engaging formats to move drug candidates closer to approval. It delivers the most comprehensive science, the most innovative technologies, and the best partners enabling scientists and engineers to reach new heights of clinical and commercial success. IBC USA is an Informa company. To learn more, visit www.IBCLifeSciences.com/BPI.
###
For more information, contact:
Howard Choi
Marketing Manager, Life Sciences Group
508.614.1494
hchoi@ibcusa.com
Phylicia Clifton
Marketing Communications Manager
646.895.7340
pclifton@iirusa.com